Innovation Partner Roundtable – Targeting the Root, Not Just the Rhythm: Next-Generation Strategies for PKP2-ACM – Powered by Lexeo

September 05, 2025 | 09:45 AM (EDT) - 10:30 AM (EDT)

Share This event

Speakers
Dominic Abrams
Co-Director of the Center for Cardiovascular Genetics
Boston Children’s Hospital
David Duncker, MD, FHRS
Head of Hannover Heart Rhythm Center
Hannover Medical School
 Faisal Merchant 
Director of Cardiac Electrophysiology and Associate Professor of Medicine
Emory Healthcare
Moderator
Andrew Krahn
Professor of Medicine
University of British Columbia

Innovation Partner Roundtable - Targeting the Root, Not Just the Rhythm: Next-Generation Strategies for PKP2-ACM - Powered by Lexeo

Roundtable 2
September 05, 2025 | 09:45 AM (EDT) - 10:30 AM (EDT)

Arrhythmogenic cardiomyopathy (ACM) is a rare, inherited cardiac disorder associated with ventricular arrhythmias, fibrofatty myocardial replacement, and sudden cardiac death (SCD). Mutations in the plakophilin-2 (PKP2) gene are the most common cause of ACM. Currently, there are no diseasemodifying therapies for PKP2-ACM; standard care focuses on arrhythmia control and SCD prevention through antiarrhythmics, ICDs, and ablation, without addressing the underlying cause.

Powered by Lexeo

Lexeo Therapeutics Logo